Program
TQB2101
A development code. Also written as “TQB2101 for Injection” and “TQB2101 for injection”.
In Sino Biopharmaceutical's pipeline, ROR1 ADC
. Its studies are mostly in Breast Neoplasms, led by Sino Biopharmaceutical.
Furthest: phase 1, since Apr 17, 20252 company-led studies, 2 open or running
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Sino Biopharmaceutical | 22 open or running | phase 1since Apr 17, 2025 | Apr 17, 2025 | none ahead |
- Named in Sino Biopharmaceutical’s own pipeline as
TQB2101
, phase 1, as of Nov 16, 2026 (source).
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Apr 17, 2025First study: phase 1 study in Breast NeoplasmsFirst studyNCT06948539 · 66 planned · China
- Jul 31, 2025Phase 1 study in Advanced Hematologic MalignanciesNCT07113925 · 114 planned · China
TargetBeta
“ROR1 ADC”the company's pipeline, read by Claude · source
Other programs on ROR1
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| zilovertamab vedotin | Merck | phase 3 | 10 |
| Anti-ROR1/Anti-CD3 Bispecific Antibody EMB-07rule | shanghai-epimab-biotherapeutics-co-ltd | phase 2 | 2 |
| Anti-ROR1 Antibody-drug Conjugate IM-1021rule | Immunome | phase 1 | 1 |
| Anti-B7-H3/Anti-ROR1-Exatecan Bispecific Antibody-drug Conjugate NEOK001rule | neok-bio-inc | phase 1 | 1 |
Studies
All 2 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07113925Advanced Hematologic Malignancies · China | 1 | Recruiting | Dec 2025 | 114 |
| NCT06948539Breast Neoplasms · China | 1 | Not yet recruiting | Oct 2026 | 66 |
How it is read
Names in the registry
- “TQB2101 for Injection”, 1 entry
- “TQB2101 for injection”, 1 entry
Codes read as this program: TQB2101.
Conditions, from the studies’ own filings
- Breast Neoplasms, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.